2017 -- H 5738 | |
======== | |
LC001921 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2017 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Representatives Canario, Edwards, Bennett, Johnston, and O`Grady | |
Date Introduced: March 01, 2017 | |
Referred To: House Judiciary | |
(Attorney General) | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform |
2 | Controlled Substances Act" is hereby amended to read as follows: |
3 | 21-28-2.08. Contents of schedules. |
4 | Schedule I |
5 | (a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
6 | common or usual name, chemical name, or brand name designated, listed in this section. |
7 | (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
8 | following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and |
9 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
10 | specific chemical designation: |
11 | (1) Acetylmethadol |
12 | (2) Allylprodine |
13 | (3) Alphacetylmethadol |
14 | (4) Alphameprodine |
15 | (5) Alphamethadol |
16 | (6) Benzethidine |
17 | (7) Betacetylmethadol |
18 | (8) Betameprodine |
19 | (9) Betamethadol |
| |
1 | (10) Betaprodine |
2 | (11) Clonitazene |
3 | (12) Dextromoramide |
4 | (13) Difenoxin |
5 | (14) Diampromide |
6 | (15) Diethylthiambutene |
7 | (16) Dimenoxadol |
8 | (17) Dimepheptanol |
9 | (18) Dimethylthiambutene |
10 | (19) Dioxaphetyl butyrate |
11 | (20) Dipipanone |
12 | (21) Ethylmethylthiambutene |
13 | (22) Etonitazene |
14 | (23) Extoxerdine |
15 | (24) Furethidine |
16 | (25) Hydroxypethidine |
17 | (26) Ketobemidone |
18 | (27) Levomoramide |
19 | (28) Levophenacylmorphan |
20 | (29) Morpheridine |
21 | (30) Noracymethadol |
22 | (31) Norlevorphanol |
23 | (32) Normethadone |
24 | (33) Norpipanone |
25 | (34) Phenadoxone |
26 | (35) Phenampromide |
27 | (36) Phenomorphan |
28 | (37) Phenoperidine |
29 | (38) Piritramide |
30 | (39) Proheptazine |
31 | (40) Properidine |
32 | (41) Propiram |
33 | (42) Racemoramide |
34 | (43) Trimeperidone |
| LC001921 - Page 2 of 18 |
1 | (44) Tilidine |
2 | (45) Alpha-methylfentanyl |
3 | (46) Beta-hydroxy-3-methylfentanyl other names: |
4 | N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl] Nphenylpropanamide |
5 | (47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- |
6 | phenylpropanamide) |
7 | (48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and |
8 | geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl) |
9 | (49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide |
10 | (Other names: beta-hydroxythiofentanyl) |
11 | (50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl) |
12 | (51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl |
13 | fentanyl) |
14 | (52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (Other names: |
15 | AH-7921) |
16 | (53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names: |
17 | U-47700) |
18 | (54) 3-Methylbutyrfentanyl (Other names: 3-MBF) |
19 | (55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF) |
20 | (56) 4-Phenylfentanyl |
21 | (57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF) |
22 | (58) Acrylfentanyl (Other names: acryloyfentanyl) |
23 | (59) Lofentanyl |
24 | (60) N-Methylcarfentanyl |
25 | (61) Ocfentanyl (INN, A-3217) |
26 | (63) 4-methoxymethylfentanyl (Other names: R-30490) |
27 | (64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6) |
28 | (c) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, |
29 | any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the |
30 | existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
31 | designation: |
32 | (1) Acetorphine |
33 | (2) Acetyldihydrocodeine |
34 | (3) Benzylmorphine |
| LC001921 - Page 3 of 18 |
1 | (4) Codeine methylbromide |
2 | (5) Codeine-N-Oxide |
3 | (6) Cyprenorphine |
4 | (7) Desomorphine |
5 | (8) Dihydromorphine |
6 | (9) Etorphine (Except hydrochloride salt) |
7 | (10) Heroin |
8 | (11) Hydromorphinol |
9 | (12) Methyldesorphine |
10 | (13) Methylihydromorphine |
11 | (14) Morphine methylbromide |
12 | (15) Morphine methylsulfonate |
13 | (16) Morphine-N-Oxide |
14 | (17) Myrophine |
15 | (18) Nococodeine |
16 | (19) Nicomorphine |
17 | (20) Normorphine |
18 | (21) Pholcodine |
19 | (22) Thebacon |
20 | (23) Drotebanol |
21 | (d) Hallucinogenic Substances. Unless specifically excepted or unless listed in another |
22 | schedule, any material, compound, mixture, or preparation that contains any quantity of the |
23 | following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers |
24 | whenever the existence of the salts, isomers, and salts of isomers is possible within the specific |
25 | chemical designation (for purposes of this subsection only, the term "isomer" includes the optical, |
26 | position, and geometric isomers): |
27 | (1) 3, 4-methylenedioxy amphetamine |
28 | (2) 5-methoxy-3, 4-methylenedioxy amphetamine |
29 | (3) 3, 4, 5-trimethoxy amphetamine |
30 | (4) Bufotenine |
31 | (5) Diethyltryptamine |
32 | (6) Dimethyltryptamine |
33 | (7) 4-methyl 2, 5-dimethoxyamphetamine |
34 | (8) Ibogaine |
| LC001921 - Page 4 of 18 |
1 | (9) Lysergic acid diethylamide |
2 | (10) Marihuana |
3 | (11) Mescaline |
4 | (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora |
5 | Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the |
6 | plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its |
7 | seeds or extracts. |
8 | (13) N-ethyl-3-piperidyl benzilate |
9 | (14) N-methyl-3-piperidyl benzilate |
10 | (15) Psilocybin |
11 | (16) Psilocyn |
12 | (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the |
13 | plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and |
14 | their isomers with similar chemical structure and pharmacological activity such as the following: |
15 | delta 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans |
16 | tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and |
17 | their optical isomer. (Since nomenclature of these substances is not internationally standardized, |
18 | compounds of these structures, regardless of numerical designation of atomic positions covered). |
19 | (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2- |
20 | Thienyl analog of phencyclidine: TPCP |
21 | (19) 2,5 dimethoxyamphetamine |
22 | (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha- |
23 | methylphenethyamine: 4-bromo-2,5-DMA |
24 | (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: |
25 | paramethoxyamphetamine: PMA |
26 | (22) Ethylamine analog of phencyclidine. N-ethyl-1- phenylcyclohexylamine, (1- |
27 | phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE |
28 | (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)- pyrrolidine PCPy, PHP |
29 | (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- |
30 | trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. |
31 | (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part |
32 | of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall |
33 | not mean the unaltered plant. |
34 | (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of |
| LC001921 - Page 5 of 18 |
1 | the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not |
2 | mean the unaltered plant. |
3 | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
4 | material, compound, mixture, or preparation that contains any quantity of the following |
5 | substances having a depressant effect on the central nervous system, including its salts, isomers, |
6 | and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible |
7 | within the specific chemical designation: |
8 | (1) Mecloqualone. |
9 | (2) Methaqualone. |
10 | (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. |
11 | (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and |
12 | geometric isomers, salts, and salts of isomers. |
13 | (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and |
14 | salts of isomers. |
15 | (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, |
16 | and salts of isomers. |
17 | (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-alpha- |
18 | methylfentanyl), its optical isomers, salts, and salts of isomers. |
19 | (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha- |
20 | methylthiofentanyl), its optical isomers, salts, and salts of isomers. |
21 | (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
22 | salts, and salts of isomers. |
23 | (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
24 | hydroxyfentanyl), its optical isomers, salts, and salts of isomers. |
25 | (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
26 | hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers. |
27 | (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro- panamide (3- |
28 | methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers. |
29 | (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
30 | optical isomers, salts, and salts of isomers. |
31 | (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
32 | isomers, salts, and salts of isomers. |
33 | (15) N-[1-(2-phenylethyl)-4-piperidyl] N-(4-fluorophenyl)-propanamid e (para- |
34 | fluorofentanyl), its optical isomers, salts, and salts of isomers. |
| LC001921 - Page 6 of 18 |
1 | (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
2 | geometric isomers, salts, and salts of isomers. |
3 | (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
4 | material, compound, mixture, or preparation that contains any quantity of the following |
5 | substances having a stimulant effect on the central nervous system, including its salts, isomers, |
6 | and salts of isomers: |
7 | (1) Fenethylline |
8 | (2) N-ethylamphetamine |
9 | (3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
10 | (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
11 | (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
12 | (g) Any material, compound, mixture, or preparation that contains any quantity of the |
13 | following substances: |
14 | (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol (CP-47,497) |
15 | (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol |
16 | (cannabicyclohexanol and CP-47,497 c8 homologue) |
17 | (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
18 | (4) 1-[2-(4-Morpholinyl)ethyl] 3-(1-naphthoyl)indole (JWH-200) |
19 | (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
20 | (h) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |
21 | compound which is not approved by the United States Food and Drug Administration or, if |
22 | approved, which is not dispensed or possessed in accordance with state and federal law, that |
23 | contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
24 | Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- |
25 | Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following |
26 | structural classes: |
27 | (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
28 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
29 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
30 | group, whether or not further substituted in the indole ring to any extent and whether or not |
31 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
32 | limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
33 | 2201; |
34 | (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
| LC001921 - Page 7 of 18 |
1 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
2 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
3 | group whether or not further substituted in the indole ring to any extent and whether or not |
4 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
5 | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
6 | (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with |
7 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
8 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
9 | group whether or not further substituted in the indole ring to any extent and whether or not |
10 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
11 | limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
12 | (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
13 | structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
14 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
15 | group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
16 | class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
17 | (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) |
18 | methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
19 | alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
20 | morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |
21 | whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
22 | include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
23 | (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure |
24 | with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
25 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
26 | group whether or not further substituted in the pyrrole ring to any extent and whether or not |
27 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
28 | limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
29 | (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
30 | structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
31 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
32 | group whether or not further substituted in the indene ring to any extent and whether or not |
33 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
34 | limited to, JWH-176; or |
| LC001921 - Page 8 of 18 |
1 | (8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
2 | States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
3 | accordance with state and federal law; |
4 | (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
5 | not approved by the United States Food and Drug Administration or, if approved, which is not |
6 | dispensed or possessed in accordance with state and federal law, not including bupropion, |
7 | structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either |
8 | phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in |
9 | one or more of the following ways: |
10 | (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
11 | haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system |
12 | by one or more other univalent substituents. Examples of this class include, but are not limited to, |
13 | 3,4-Methylenedioxycathinone (bk-MDA); |
14 | (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
15 | class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
16 | (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
17 | methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
18 | Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and a- |
19 | Pyrrolidinopropiophenone (a-PPP); or |
20 | (4) Any other synthetic cathinone which is not approved by the United States Food and |
21 | Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
22 | federal law; |
23 | Schedule II |
24 | (a) Schedule II shall consist of the drugs and other substances, by whatever official name, |
25 | common or usual name, chemical name, or brand name designated, listed in this section. |
26 | (b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or |
27 | unless listed in another schedule, any of the following substances whether produced directly or |
28 | indirectly by extraction from substances of vegetable origin, or independently by means of |
29 | chemical synthesis, or by a combination of extraction and chemical synthesis: |
30 | (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
31 | opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
32 | following: |
33 | (i) Raw opium |
34 | (ii) Opium extracts |
| LC001921 - Page 9 of 18 |
1 | (iii) Opium fluid extracts |
2 | (iv) Powdered opium |
3 | (v) Granulated opium |
4 | (vi) Tincture of opium |
5 | (vii) Etorphine hydrochloride |
6 | (viii) Codeine |
7 | (ix) Ethylmorphine |
8 | (x) Hydrocodone |
9 | (xi) Hydromorphone |
10 | (xii) Metopon |
11 | (xiii) Morphine |
12 | (xiv) Oxycodone |
13 | (xv) Oxymorphone |
14 | (xvi) Thebaine |
15 | (2) Any salt, compound, derivative, or preparation that is chemically equivalent or |
16 | identical with any of the substances referred to in subdivision (1) of this subsection, except that |
17 | these substances shall not include the isoquinoline alkaloids of opium. |
18 | (3) Opium poppy and poppy straw. |
19 | (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and |
20 | any salt, compound, derivative, or preparation that is chemically equivalent or identical with any |
21 | of these substances, except that the substances shall not include decocainized coca leaves or |
22 | extraction of coca leaves, which extractions do not contain cocaine or ecgonine. |
23 | (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or |
24 | powder form that contains the phenanthrine alkaloids of the opium poppy). |
25 | (c) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
26 | following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and |
27 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
28 | specific chemical designation: |
29 | (1) Alphaprodine |
30 | (2) Anileridine |
31 | (3) Bezitramide |
32 | (4) Dihydrocodeine |
33 | (5) Diphenoxylate |
34 | (6) Fentanyl |
| LC001921 - Page 10 of 18 |
1 | (7) Isomethadone |
2 | (8) Levomethorphan |
3 | (9) Levorphanol |
4 | (10) Metazocine |
5 | (11) Methadone |
6 | (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
7 | (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
8 | acid |
9 | (14) Pethidine |
10 | (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
11 | (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
12 | (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
13 | (18) Phenaxocine |
14 | (19) Piminodine |
15 | (20) Racemethorphan |
16 | (21) Racemorphan |
17 | (22) Bulk Dextropropoxyphene (non-dosage forms) |
18 | (23) Suffentanil |
19 | (24) Alfentanil |
20 | (25) Levoalphacetylmethadol |
21 | (26) Carfentanil |
22 | (27) Remifentanil |
23 | (d) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
24 | material, compound, mixture, or preparation that contains any quantity of the following |
25 | substances having a stimulant effect on the central nervous system: |
26 | (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
27 | (2) Methamphetamine, its salts, and salts of its isomers. |
28 | (3) Phenmetrazine and its salts. |
29 | (4) Methylphenidate. |
30 | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
31 | material, compound, mixture, or preparation that contains any quantity of the following |
32 | substances having a depressant effect on the central nervous system, including its salts, isomers, |
33 | and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible |
34 | within the specific chemical designation: |
| LC001921 - Page 11 of 18 |
1 | (1) Amobarbital |
2 | (2) Glutethimide |
3 | (3) Methyprylon |
4 | (4) Pentobarbital |
5 | (5) Phencyclidine |
6 | (6) Secobarbital |
7 | (7) Phencyclidine immediate precursors: |
8 | (i) 1-phencyclohexylamine |
9 | (ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
10 | (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
11 | other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
12 | Schedule III |
13 | (a) Unless specifically excepted or unless listed in another schedule, any material, |
14 | compound, mixture, or preparation that contains any quantity of the following substances having |
15 | a depressant effect on the central nervous system: |
16 | (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt |
17 | of a derivative of barbituric acid. |
18 | (2) Chlorhexadol |
19 | (3) Lysergic acid |
20 | (4) Lysergic acid amide |
21 | (5) Sulfondiethylmethane |
22 | (6) Sulfonethylmethane |
23 | (7) Sylfonmethane |
24 | (8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
25 | pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not |
26 | listed in any schedule. |
27 | (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or |
28 | any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
29 | only as a suppository. |
30 | (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine: |
31 | (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
32 | (b) Unless specifically excepted or unless listed in another schedule, any material, |
33 | compound, mixture, or preparation containing limited quantities of any of the following narcotic |
34 | drugs, or any salts of them: |
| LC001921 - Page 12 of 18 |
1 | (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
2 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
3 | or greater quantity of an isoquinoline alkaloid of opium. |
4 | (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
5 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
6 | more active, nonnarcotic ingredients in recognized therapeutic amounts. |
7 | (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
8 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
9 | a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
10 | (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
11 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
12 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
13 | (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one |
14 | hundred milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with |
15 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
16 | (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one |
17 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
18 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
19 | (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred |
20 | milliliters (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five |
21 | milligrams (25 mgs.) per dosage unit, with one or more active nonnarcotic ingredients in |
22 | recognized therapeutic amounts. |
23 | (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100 |
24 | mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
25 | recognized therapeutic amounts. |
26 | (c) Stimulants. Unless specifically excepted or listed in another schedule, any material, |
27 | compound, mixture, or preparation that contains any quantity of the following substances having |
28 | a stimulant effect on the central nervous system, including its salts, isomers, and salts of the |
29 | isomers whenever the existence of the salts of isomers is possible within the specific chemical |
30 | designation: |
31 | (1) Benzphetamine |
32 | (2) Chlorphentermine |
33 | (3) Clortermine |
34 | (4) Mazindol |
| LC001921 - Page 13 of 18 |
1 | (5) Phendimetrazine |
2 | (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH), |
3 | excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
4 | of its concentration, preparation, mixture, or delivery system, has no significant potential for |
5 | abuse, as published in 21 CFR 1308.34, including, but not limited to, the following: |
6 | (1) Chlorionic gonadotropin |
7 | (2) Clostebol |
8 | (3) Dehydrochlormethyltestosterone |
9 | (4) Ethylestrenol |
10 | (5) Fluoxymesterone |
11 | (6) Mesterolone |
12 | (7) Metenolone |
13 | (8) Methandienone |
14 | (9) Methandrostenolone |
15 | (10) Methyltestosterone |
16 | (11) Nandrolone decanoate |
17 | (12) Nandrolone phenpropionate |
18 | (13) Norethandrolone |
19 | (14) Oxandrolone |
20 | (15) Oxymesterone |
21 | (16) Oxymetholone |
22 | (17) Stanozolol |
23 | (18) Testosterone propionate |
24 | (19) Testosterone-like related compounds |
25 | (20) Human Growth Hormone (HGH) |
26 | (e) Hallucinogenic substances. |
27 | (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S. |
28 | Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR- |
29 | trans)-6a, 7, 8, 10a- tetrahydro-6, 6, 9- trimethyl-3-pentyl-6H- dibenzo[b,d] yra n-1-ol,or(-)-delta- |
30 | 9(trans)-tetrahydrocannabinol.) |
31 | Schedule IV |
32 | (1) Barbital. |
33 | (2) Chloral betaine |
34 | (3) Chloral hydrate |
| LC001921 - Page 14 of 18 |
1 | (4) Ethchrovynol |
2 | (5) Ethinamate |
3 | (6) Methohexital |
4 | (7) Meprobamate |
5 | (8) Methylphenobarbital |
6 | (9) Paraldehyde |
7 | (10) Petrichloral |
8 | (11) Phenobarbital |
9 | (12) Fenfluramine |
10 | (13) Diethylpropion |
11 | (14) Phentermine |
12 | (15) Pemoline (including organometallic complexes and chelates thereof). |
13 | (16) Chlordiazepoxide |
14 | (17) Clonazepam |
15 | (18) Clorazepate |
16 | (19) Diazepam |
17 | (20) Flurazepam |
18 | (21) Mebutamate |
19 | (22) Oxazepam |
20 | (23) Unless specifically excepted or unless listed in another schedule, any material, |
21 | compound, mixture, or preparation that contains any quantity of the following substances, |
22 | including its salts: |
23 | Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3- methyl-2- |
24 | propronoxybutane). |
25 | (24) Prazepam |
26 | (25) Lorazepam |
27 | (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
28 | micrograms of atropine sulfate per dosage unit. |
29 | (27) Pentazocine |
30 | (28) Pipradrol |
31 | (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
32 | (30) Temazepam |
33 | (31) Halazepam |
34 | (32) Alprazolam |
| LC001921 - Page 15 of 18 |
1 | (33) Bromazepam |
2 | (34) Camazepam |
3 | (35) Clobazam |
4 | (36) Clotiazepam |
5 | (37) Cloxazolam |
6 | (38) Delorazepam |
7 | (39) Estazolam |
8 | (40) Ethyl Ioflazepate |
9 | (41) Fludizaepam |
10 | (42) Flunitrazepam |
11 | (43) Haloxazolam |
12 | (44) Ketazolam |
13 | (45) Loprazolam |
14 | (46) Lormetazepam |
15 | (47) Medazepam |
16 | (48) Nimetazepam |
17 | (49) Nitrazepam |
18 | (50) Nordiazepam |
19 | (51) Oxazolam |
20 | (52) Pinazepam |
21 | (53) Tetrazepam |
22 | (54) Mazindol |
23 | (55) Triazolam |
24 | (56) Midazolam |
25 | (57) Quazepam |
26 | (58) Butorphanol |
27 | (59) Sibutramine |
28 | Schedule V |
29 | (a) Any compound, mixture, or preparation containing any of the following limited |
30 | quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
31 | ingredients in sufficient proportion to confer upon the compound, mixture, or preparation |
32 | valuable medicinal qualities other than those possessed by the narcotic drug alone: |
33 | (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
34 | mls.) or per one hundred grams (100 gms.). |
| LC001921 - Page 16 of 18 |
1 | (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 |
2 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
3 | (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 |
4 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
5 | (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
6 | than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
7 | (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred |
8 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
9 | (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty- |
10 | five (25) micrograms of atropine sulfate per dosage unit. |
11 | (c) Buprenorphine |
12 | (d) Unless specifically exempted or excluded or unless listed in another schedule, any |
13 | material, compound, mixture, or preparation that contains any quantity of the following |
14 | substances having a stimulant effect on the central nervous system, including its salts, isomers, |
15 | and salts of isomers: |
16 | (1) Propylhexedrine (except as benzedrex inhaler) |
17 | (2) Pyrovalerone. |
18 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC001921 | |
======== | |
| LC001921 - Page 17 of 18 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would include fentanyl analogs and synthetic opioids into Schedule I and |
2 | Schedule II of the list of uniform controlled substances. |
3 | This act would take effect upon passage. |
======== | |
LC001921 | |
======== | |
| LC001921 - Page 18 of 18 |